Lumos Pharma Inc

NASDAQ:LUMO  
7.75
-0.10 (-1.27%)
Other Pre-Announcement

Lumos Pharma Reports First Quarter 2022 Financial Results And Clinical Development Updates

Published: 05/10/2022 21:33 GMT
Lumos Pharma Inc (LUMO) - Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates.
Ended Quarter on March 31, 2022 With Cash and Cash Equivalents Totaling $86.8 Million.
Expects an Average Cash Use of Approximately $8.5 to $9.5 Million per Quarter Through 2022.
Q1 Earnings per Share View $-0.89 -- Refinitiv Ibes Data (analyst estimates).